Drugs / CC-96191
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04789655 | Jun 2021 → Apr 2025 | myeloid leukemia | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-96191 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04789655 ↗ |
| Action | Deplete | “CC-96191 eliminated AML cells but not normal monocytes” PMID 38473239 ↗ Feb 2024 |
| Modality | Other / unclassified | “a novel CD33/CD16a/NKG2D immune-modulating TriNKET® CC-96191.” PMID 38473239 ↗ Feb 2024 |
| Route | Intravenous | “CC-96191 will be administered intravenously on a 28-day Cycle” NCT04789655 ↗ |
| Target | CD33 | “CC-96191 simultaneously binds CD33, NKG2D, and CD16a” PMID 38473239 ↗ Feb 2024 |